NVS:NYSE
Novartis AG
$141.00
arrow_upward
+0.01%(+0.0100) 1D
$141.00
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:03 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVS...
Open
$141.46
High
$141.57
Low
$139.95
Mkt. cap
289.09B
Avg. vol.
2.27M
Volume
2.25M
Dividend
3.36%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
21.30
52-wk high
$170.46
52-wk low
$121.57
EPS
$6.62
Beta
0.39
Shares outstanding
2.03B
No. of employees
75K
Open
$141.46
High
$141.57
Low
$139.95
Mkt. cap
289.09B
Avg. vol.
2.27M
Volume
2.25M
Dividend
3.36%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
21.30
52-wk high
$170.46
52-wk low
$121.57
EPS
$6.62
Beta
0.39
Shares outstanding
2.03B
No. of employees
75K
News stories
From web sources and news partners
AD HOC NEWS
·
15 hours ago
Novartis stock after-hours at EUR 124.52: minus 0.90 percent versus Lang & Schwarz prior close
Zacks
·
17 hours ago
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Euronext Markets: Real-time Stock Market Data | live
·
17 hours ago
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Analyst ratings
Based on 6 analysts giving stock ratings to NVS in the past 3 months
Hold
Buy
2
Hold
3
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current $141.00
$180.39 (+27.94%)
Average
$158.73 (+12.57%)
Lowest
$136.00 (-3.55%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Rajesh Kumar HSBC | Hold | Upgraded | $136.00 | -3.5% | 09/10/2026 |
Steve Scala TD Cowen | Hold | Maintained | $180.00 | +27.7% | 09/08/2026 |
Sachin Jain Bank of America Securities | Buy | Maintained | CHF 150.00 | +6.4% | 09/07/2026 |
Kerry Holford Berenberg Bank | Hold | Maintained | $147.00 | +4.3% | 07/27/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | $170.00 | +20.6% | 07/24/2026 |
Unknown Analyst Goldman Sachs | Sell | Maintained | $139.00 | -1.4% | 07/22/2026 |
Thibault Boutherin Morgan Stanley | Buy | Maintained | $170.00 | +20.6% | 03/26/2026 |
Justin Smith Bernstein | Hold | Initiated | - | - | 03/19/2026 |
David Toung Argus Research | Buy | Upgraded | $180.00 | +27.7% | 03/11/2026 |
Last report
Jul 21, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.41 / $2.15
+12.21%beat
arrow_upward
Revenue / Est. (USD)
14.95B / 14.06B
+6.36%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 14.36B | 13.86B | 13.52B | 14.95B |
Cost of goods sold | 3.54B | 3.54B | 3.44B | 3.68B |
Cost of revenue | 3.54B | 3.54B | 3.44B | 3.68B |
Research and development expenses | 2.86B | 2.84B | 2.78B | 2.74B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.30B | 3.44B | 3.14B | 3.23B |
Operating expense | 6.24B | 6.46B | 5.96B | 6.10B |
Total operating expenses | 9.77B | 10.00B | 9.40B | 9.78B |
Operating income | 4.58B | 3.86B | 4.12B | 5.18B |
Other non operating income | -7.00M | -130.00M | 4.00M | 19.00M |
EBT including unusual items | 4.20B | 3.22B | 3.84B | 4.27B |
EBT excluding unusual items | 4.29B | 3.49B | 3.78B | 4.73B |
Income tax expense | 266.00M | 814.00M | 683.00M | 1.01B |
Effective tax rate | 6.34% | 25.30% | 17.79% | 23.71% |
Other operating expenses | 70.00M | 190.00M | 42.00M | 127.00M |
Net income | 3.93B | 2.41B | 3.16B | 3.26B |
Net profit margin | 27.36% | 17.38% | 23.34% | 21.83% |
Earnings per share | 2.25 | 2.03 | 1.99 | 2.41 |
Interest and investment income | - | 373.00M | - | - |
Interest expense | -281.00M | -304.00M | -343.00M | -462.00M |
Net interest expenses | -281.00M | 69.00M | -343.00M | -462.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 5.78B | 4.96B | 5.24B | 6.30B |
Gain or loss from assets sale | 81.00M | 80.00M | -159.00M | -247.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1